A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK

References

• Summary of Product Characteristics: Gilenya 0.5 mg hard capsules. London: European Medicines Agency, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf. Accessed October 30, 2015
   Google Scholar
• Summary of Product Characteristics: Tysabri 300 mg concentrate for solution for infusion. London: European Medicines Agency, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf. Accessed October 30, 2015
   Google Scholar
• Mackenzie IS, Morant SV, Bloomfield GA, et al. Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry 2014;85:76-84
   PubMed Web of Science ®Google Scholar
• Kingwell E, Marriott JJ, Jette N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013;13:128
   PubMed Web of Science ®Google Scholar
• Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-8
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278-86
   PubMed Web of Science ®Google Scholar
• Gani R, Nixon RM, Hughes S, et al. Estimating the rates of disability progression in people with active relapsing-remitting multiple sclerosis. J Med Econ 2007;10:79-89
   Google Scholar
• McCrone P, Heslin M, Knapp M, et al. Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics 2008;26:847-60
   PubMed Web of Science ®Google Scholar
• Montgomery S, Kusel J, Allen F, et al. Paucity and inconsistency: a systematic review and critique of budget impact analyses of disease-modifying therapies for multiple sclerosis in the UK and the implications for policy in the UK. Appl Health Econ Health Policy 2016;14:545-58
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis (TA127). London, UK: NICE; 2007
   Google Scholar
• Scottish Medicines Consortium. Natalizumab 300 mg concentrate for solution for infusion (Tysabri). NHS Scotland: Glasgow; 2007
   Google Scholar
• Scottish Medicines Consortium. Fingolimod (Gilenya). NHS Scotland: Glasgow; 2014
   Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545-56
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Alemtuzumab for treating relapsing-remitting multiple sclerosis (TA312). London, UK: NICE; 2014
   Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39
   PubMed Web of Science ®Google Scholar
• Maruszczak MJ, Montgomery SM, Griffiths MJ, et al. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. J Med Econ 2015;18:874-85
   PubMed Web of Science ®Google Scholar
• Allen F, Montgomery S, Maruszczak M, et al. Convergence yet continued complexity: a systematic review and critique of health economic models of relapsing-remitting multiple sclerosis in the United Kingdom. Value Health 2015;18:925-38
   PubMed Web of Science ®Google Scholar
• Caro JJ, Moller J. Advantages and disadvantages of discrete-event simulation for health economic analyses. Expert Rev Pharmacoecon Outcomes Res 2016;16:327-9
   PubMed Web of Science ®Google Scholar
• Karnon J, Haji Ali Afzali H. When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES. Pharmacoeconomics 2014;32:547-58
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis (TA254). London, UK: NICE; 2012
   Google Scholar
• National Institute for Health and Care Excellence. Teriflunomide for treating relapsing-remitting multiple sclerosis (TA303). London, UK: NICE; 2014
   Google Scholar
• National Institute for Health and Care Excellence. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320). London, UK: NICE; 2014
   Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Care Excellence, 2015; http://www.nice.org.uk/article/pmg9/. Accessed October 30, 2015
   Google Scholar
• Association of British Neurologists. Guidelines for prescribing in multiple sclerosis. London, UK: Association of British Neurologists; 2009
   Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt1):133-46
   Google Scholar
• Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009;256:405-15
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Gilenya: EPAR - Assessment Report; 2011. London, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/WC500104529.pdf Accessed October 30, 2015
   Google Scholar
• Novartis. Data on file: HR vs placebo for 3-month confirmed disability progression (with the definition of progression adjusted to match that from the AFFIRM trial), pooled FREEDOMS + FREEDOMS II RES sub-group, Camberley, Surrey 2016
   Google Scholar
• NHS. National Schedule of Reference Costs 2014–15 for NHS trusts and NHS foundation trusts. London, UK: NHS; 2015
   Google Scholar
• NHS. NHS Tariff 2014–15. London, UK: NHS; 2015
   Google Scholar
• Biogen Idec Ltd. Natalizumab (Tysabri(r)) for the treatment of adults with highly active relapsing remitting multiple sclerosis. Manufacturer submission of evidence to NICE. London, UK: National Institute for Health and Clinical Excellence: TA127; 2007
   Google Scholar
• National Institute for Health and Care Excellence. List of technologies with approved Patient Access Schemes. London: National Institute for Health and Care Excellence, https://www.nice.org.uk/about/what-we-do/patient-access-schemes-liaison-unit/list-of-technologies-with-approved-patient-access-schemes. Accessed November 30, 2016
   Google Scholar
• Curtis L, Burns A. Unit costs of health and social care 2015. Canterbury,Kent: University of Kent, 2015
   Google Scholar
• Genzyme. Alemtuzumab for the treatment of relapsing remitting multiple sclerosis in adults. Manufacturer submission of evidence. London, UK: National Institute for Health and Care Excellence: TA312; 2013
   Google Scholar
• Dong-Si T, Gheuens S, Gangadharan A, et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol 2015;21:637-44
   PubMed Web of Science ®Google Scholar
• McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016;87:117-25
   PubMed Web of Science ®Google Scholar
• Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60
   PubMed Web of Science ®Google Scholar
• Genzyme. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis in adults. Manufacturer submission of evidence. London, UK: National Institute for Health and Care Excellence: TA303; 2013
   Google Scholar
• Novartis Pharmaceuticals UK Ltd. Fingolimod for the treatment of relapsing remitting multiple sclerosis in adults. Manufacturer submission of evidence. London, UK: National Institute for Health and Clinical Excellence: TA254; 2011
   Google Scholar
• Espallargues M, Czoski-Murray CJ, Bansback NJ, et al. The impact of age-related macular degeneration on health status utility values. Invest Ophthalmol Vis Sci 2005;46:4016-23
   PubMed Web of Science ®Google Scholar
• Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 2005;14:1169-89
   PubMed Web of Science ®Google Scholar
• Currie CJ, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005;8:581-90
   PubMed Web of Science ®Google Scholar
• Putzki N. Characteristics of PML cases in multiple sclerosis patients switching to fingolimod from natalizumab. Presented at the 6th Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, September 10–13, 2014, Boston, MA
   Google Scholar
• Biogen Idec. TYSABRI (natalizumab) Benefit/risk update & PML risk stratification. Reactive presentation for healthcare professionals (approval number: TY-PAN-0683(2) Date: September 2015). Cambridge: Massachusetts http://www.slideshare.net/gavingiovannoni/tysabri-benefit-risk-update-q3-2015/. Accessed May 20, 2016
   Google Scholar
• Raffel J, Gafson AR, Malik O, et al. Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler 2015;21:1833-8
   PubMed Web of Science ®Google Scholar
• Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open 2014;4:e004073
   PubMed Web of Science ®Google Scholar
• Kusel J, Maruszczak M, Adlard N. Cost-utility of fingolimod compared with dimethyl fumarate (Dmf) in highly active relapsing remitting multiple sclerosis (Rrms) in England: comparison of a Markov and discrete event simulation model. Value Health 2015;18:A759
   PubMed Web of Science ®Google Scholar
• Coles AJ, Arnold DL, Cohen JA, et al. Patients with active RRMS and an inadequate response to prior therapy demonstrate durable improvements in relapse and disability following treatment with alemtuzumab: 5-year follow-up of the CARE-MS II study. Presented at the 68th Annual Meeting of the American Academy of Neurology, April 15–21, 2016, Vancouver, BC, Canada
   Google Scholar
• Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 2015;86:208-15
   PubMed Web of Science ®Google Scholar